Inside the AMD Trials What to Look for

Thomas, Edger L.
December 2005
Review of Ophthalmology;Dec2005, Vol. 12 Issue 12, Special section p2
Trade Publication
The article presents information on age-related macular degeneration (AMD) trials. AMD is a very complex pathobiologic process which involves angiogenic, cellular, structural and cicatical factors. The earliest treatment for curing AMD is photocoagulation. Recently, diabetic retinopathy became a well-classified and studied disease. The categorization and classification of diabetic retinopathy into a rational grading system was done, so that it could be used for subsequent clinical trials to determine whether and how best photocoagulation could be applied. This categorization and classification of diabetic retinopathy resulted into the knowledge of the Diabetic Retinopathy Study, the Diabetic Retinopathy Vitrectomy and the Early Treatment Diabetic Retinopathy clinical trials.


Related Articles

  • Waiting for study results, physicians explore ways to optimize AMD treatment. Cimberle, Michela; Nale, Pat // Ocular Surgery News;2/25/2009, Vol. 27 Issue 4, p1 

    The article reports that many physicians are exploring ways to optimize the treatment for age-related macular degeneration (AMD) while waiting for the results of a trial comparing two leading anti-vascular endothelial growth factor (VEGF) agents in the treatment of AMD. The clinical trial...

  • Pharmacologic Vitreolysis with Ocriplasmin: Rationale for Use and Therapeutic Potential in Vitreo-Retinal Disorders. Khoshnevis, Matin; Sebag, J // BioDrugs;Apr2015, Vol. 29 Issue 2, p103 

    With increased knowledge about the origins and pathophysiology of vitreo-retinal disorders-and, in particular, the central role of anomalous posterior vitreous detachment in vitreo-maculopathies-a paradigm shift from surgery to pharmacotherapy is taking place with the development of...

  • POINT/COUNTER.  // Ocular Surgery News;2/25/2009, Vol. 27 Issue 4, p11 

    The article presents opposing views on ongoing CATT studies regarding the treatment for wet age-related macular degeneration (AMD). Physician Sophie J. Bakri expects the trial results to tell if Avastin is non-inferior to Lucentis when given on a monthly basis, and if each drug is better given...

  • Putting Regeneration into Regenerative Medicine. Luna, Reyna I. Martinez-De; Zuber, Michael E. // Journal of Ophthalmic & Vision Research;2014, Vol. 9 Issue 1, p126 

    No abstract available.

  • Role of Inflammation in the Pathogenesis of Diabetic Retinopathy. Abu El-Asrar, Ahmed M. // Middle East African Journal of Ophthalmology;Jan-Mar2012, Vol. 19 Issue 1, p70 

    Diabetic retinopathy (DR) remains a major cause of worldwide preventable blindness. The microvasculature of the retina responds to hyperglycemia through a number of biochemical changes, including activation of protein kinase C, increased advanced glycation end products formation, polyol pathway,...

  • Out of the Darkness. THOO, MANDY // Australasian Science;Mar2014, Vol. 35 Issue 2, p26 

    The article reports on scientists at the ARC Centre of Excellence in Vision Science pioneering techniques that may reverse the loss of sight. They are developing fast, accurate and painless eye tests, slowing the advance of damaging eye diseases in patients. Age-related macular degeneration...

  • Recurrence of choroidal neovascularisation after photodynamic therapy in patients with age-related macular degeneration. Potter, Michael J.; Szabo, Shelagh M. // British Journal of Ophthalmology;Jun2007, Vol. 91 Issue 6, p753 

    Aim: To determine the incidence of recurrence of choroidal neovascularisation (CNV) 18 months after cessation of photodynamic therapy (PDT) with verteporfin monotherapy in patients with age-related macular degeneration (AMD). Methods: This was a prospective interventional cohort study. The...

  • Macugen, Retaane, Lucentis and Other Emerging Drugs May Soon Treat AMD.  // Review of Optometry;10/15/2004, Vol. 141 Issue 10, p6 

    The article focuses on the treatment for age-related macular degeneration (AMD). AMD products are in both the middle and late stages of development. An onslaught of diabetic macular edema and diabetic retinopathy drugs is also expected. In the case of AMD, Visudyne is currently the only...

  • Outcomes in Cochrane Systematic Reviews Addressing Four Common Eye Conditions: An Evaluation of Completeness and Comparability. Saldanha, Ian J.; Dickersin, Kay; Wang, Xue; Li, Tianjing // PLoS ONE;Oct2014, Vol. 9 Issue 10, p1 

    Introduction: Choice of outcomes is critical for clinical trialists and systematic reviewers. It is currently unclear how systematic reviewers choose and pre-specify outcomes for systematic reviews. Our objective was to assess the completeness of pre-specification and comparability of outcomes...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics